FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740553485> ?p ?o ?g. }

• W2740553485 abstract "Objectives. Human IgG3 differs from other antibody isotypes by its extended hinge region and by its higher affinity for C1q. The ability of complement to promote lysis of antibody-opsonized cells is well-established and may represent a main mechanism in antibody mediated tumor therapy. The aim of this project was to investigate effector mechanisms of tumor- directed IgG3 antibodies in more detail. Experimental procedures. Therapeutic antibodies against EGFR (cetuximab, 225) and CD20 (rituximab, C2B8) were produced as IgG1 and IgG3 isotype variants by co-transfecting CHO cells with the respective de novo synthesized VH and VL domains fused to the respective heavy chain containing vectors. A Fab fragment of C2B8-IgG3 was crystallized and analyzed by X-ray structure analysis at PETRA III (DESY, Hamburg, Germany). Based on the resolved structure selected mutations were introduced into the CH1 domain of IgG3 aiming to improve or abolish CDC. Purified antibodies were assessed for complement fixation in ELISA and on tumor cells. Complement- and antibody-dependent cellular cytotoxicity (CDC and ADCC) activities were measured using 51chromium release assays. The significance of complement regulatory factors on target cells was investigated by siRNA mediated knock-down. A peritoneal tumor model was used to investigate the in vivo efficacy of IgG3 in comparison to IgG1 antibodies. Results. Switching isotypes from IgG1 to IgG3 did neither affect target antigen binding nor the proliferation inhibition by EGFR antibodies. Unexpectedly, the IgG3 antibodies were not very active in ADCC, in spite of their strong FcγRIII (CD16) binding affinity. However, for target cells expressing low antigen levels, the IgG3 isotype improved CDC against CD20 and enabled CDC against EGFR expressing tumor cells. The complement-regulatory factor CD55 in particular mitigated the IgG3 induced CDC activity. Structural comparison of Fab fragments of IgG1 and IgG3 demonstrated significant differences in the CH1 domains of the respective heavy chains, which contain the disulfide bond to the light chain and also harbor the docking interface for the complement factors C3b and C4b. Preliminary results from an peritoneal tumor model demonstrated that 225-IgG3 was effective in killing EGFR- expressing cells. This in vivo activity was abolished by cobra venom factor treatment. Conclusion. Switching the isotype of a therapeutic IgG1 antibody to IgG3 represents a promising approach to enable complement-mediated killing of tumor cells. Protein engineering of the C3b/C4b interaction interface in the CH1 domain may constitute a novel strategy to modulate the CDC activity against tumor target cells. Together, these approaches may enhance the CDC efficacy of CD20- and EGFR- directed antibodies. Citation Format: Ralf Schwanbeck, Anna Skof, Thies Rosner, Marco Jansen, Anina Rauchle, Anna Kretschmer, Axel Scheidig, Jeanette Leusen, Stefanie Derer, Thomas Valerius. Mechanisms of action for therapeutic antibody variants of human IgG3 isotype: Enhancing the CDC activity of cetuximab and rituximab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4601. doi:10.1158/1538-7445.AM2017-4601" @default.
• W2740553485 created "2017-08-08" @default.
• W2740553485 creator A5002001213 @default.
• W2740553485 creator A5015545205 @default.
• W2740553485 creator A5022565197 @default.
• W2740553485 creator A5039149505 @default.
• W2740553485 creator A5041143781 @default.
• W2740553485 creator A5044656565 @default.
• W2740553485 creator A5054312156 @default.
• W2740553485 creator A5068320500 @default.
• W2740553485 creator A5071832455 @default.
• W2740553485 creator A5078795306 @default.
• W2740553485 date "2017-07-01" @default.
• W2740553485 modified "2023-09-25" @default.
• W2740553485 title "Abstract 4601: Mechanisms of action for therapeutic antibody variants of human IgG3 isotype: Enhancing the CDC activity of cetuximab and rituximab" @default.
• W2740553485 doi "https://doi.org/10.1158/1538-7445.am2017-4601" @default.
• W2740553485 hasPublicationYear "2017" @default.
• W2740553485 type Work @default.
• W2740553485 sameAs 2740553485 @default.
• W2740553485 citedByCount "1" @default.
• W2740553485 countsByYear W27405534852020 @default.
• W2740553485 crossrefType "proceedings-article" @default.
• W2740553485 hasAuthorship W2740553485A5002001213 @default.
• W2740553485 hasAuthorship W2740553485A5015545205 @default.
• W2740553485 hasAuthorship W2740553485A5022565197 @default.
• W2740553485 hasAuthorship W2740553485A5039149505 @default.
• W2740553485 hasAuthorship W2740553485A5041143781 @default.
• W2740553485 hasAuthorship W2740553485A5044656565 @default.
• W2740553485 hasAuthorship W2740553485A5054312156 @default.
• W2740553485 hasAuthorship W2740553485A5068320500 @default.
• W2740553485 hasAuthorship W2740553485A5071832455 @default.
• W2740553485 hasAuthorship W2740553485A5078795306 @default.
• W2740553485 hasConcept C125823703 @default.
• W2740553485 hasConcept C153911025 @default.
• W2740553485 hasConcept C159654299 @default.
• W2740553485 hasConcept C185592680 @default.
• W2740553485 hasConcept C203014093 @default.
• W2740553485 hasConcept C2777726029 @default.
• W2740553485 hasConcept C2777991845 @default.
• W2740553485 hasConcept C2779998722 @default.
• W2740553485 hasConcept C40677261 @default.
• W2740553485 hasConcept C502942594 @default.
• W2740553485 hasConcept C542903549 @default.
• W2740553485 hasConcept C86803240 @default.
• W2740553485 hasConceptScore W2740553485C125823703 @default.
• W2740553485 hasConceptScore W2740553485C153911025 @default.
• W2740553485 hasConceptScore W2740553485C159654299 @default.
• W2740553485 hasConceptScore W2740553485C185592680 @default.
• W2740553485 hasConceptScore W2740553485C203014093 @default.
• W2740553485 hasConceptScore W2740553485C2777726029 @default.
• W2740553485 hasConceptScore W2740553485C2777991845 @default.
• W2740553485 hasConceptScore W2740553485C2779998722 @default.
• W2740553485 hasConceptScore W2740553485C40677261 @default.
• W2740553485 hasConceptScore W2740553485C502942594 @default.
• W2740553485 hasConceptScore W2740553485C542903549 @default.
• W2740553485 hasConceptScore W2740553485C86803240 @default.
• W2740553485 hasLocation W27405534851 @default.
• W2740553485 hasOpenAccess W2740553485 @default.
• W2740553485 hasPrimaryLocation W27405534851 @default.
• W2740553485 hasRelatedWork W125597271 @default.
• W2740553485 hasRelatedWork W1981569750 @default.
• W2740553485 hasRelatedWork W1995118292 @default.
• W2740553485 hasRelatedWork W2001333029 @default.
• W2740553485 hasRelatedWork W2012316443 @default.
• W2740553485 hasRelatedWork W2035070408 @default.
• W2740553485 hasRelatedWork W2044953793 @default.
• W2740553485 hasRelatedWork W2051352460 @default.
• W2740553485 hasRelatedWork W2059466815 @default.
• W2740553485 hasRelatedWork W2081362512 @default.
• W2740553485 hasRelatedWork W2105141160 @default.
• W2740553485 hasRelatedWork W2128285319 @default.
• W2740553485 hasRelatedWork W2410923940 @default.
• W2740553485 hasRelatedWork W2501433828 @default.
• W2740553485 hasRelatedWork W2530818509 @default.
• W2740553485 hasRelatedWork W2616546024 @default.
• W2740553485 hasRelatedWork W2809713243 @default.
• W2740553485 hasRelatedWork W2887130186 @default.
• W2740553485 hasRelatedWork W2955565316 @default.
• W2740553485 hasRelatedWork W36801553 @default.
• W2740553485 isParatext "false" @default.
• W2740553485 isRetracted "false" @default.
• W2740553485 magId "2740553485" @default.
• W2740553485 workType "article" @default.